6533b829fe1ef96bd128974f

RESEARCH PRODUCT

Role of antiemetic prophylaxis for breast cancer (BC) patients treated with anti-HER2 or anti-VEGF monoclonal antibodies.

Giuseppe GalantiPaolo AmariGiuseppe BronteLivio BlasiVincenzo AdamoSilvana BavettaMaria Antonietta AspanãƒâMassimiliano AlùSceila AffrontiAntonio RussoAntonella UssetGiovanni Orlando

subject

Anti vegfCancer Researchbusiness.industrymedicine.drug_classmedicine.diseaseMonoclonal antibodyBreast cancerOncologyCancer researchMedicineAntiemeticAnti her2Cytotoxicitybusiness

description

e20705 Background: To date the anti-emetic prophylaxis based on the combination of 5HT3-antagonists and corticosteroids is mandatory for high and moderate emetogenic cytotoxic agents. This approach...

https://doi.org/10.1200/jco.2014.32.15_suppl.e20705